Antibody-Targeted DNA Origami Nanostructures for the treatment of Acute Myeloid Leukemia
By: Patrick Haley
Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210, USA
Hematologic malignancies remain incurable, in part, due to the development of drug resistance mechanisms. Specifically, Acute Myeloid Leukemia (AML) has a median age of diagnosis of 67 years, lowering the tolerance to dangerous side effects and increasing the need for novel new delivery methods. One solution is DNA origami, which with its precise design and versatility makes it an ideal choice for drug delivery. Previously we have shown that by loading the classic chemotherapy drug daunorubicin into DNA origami nanostructures they will bypass protein pump mechanisms of drug-resistant cells. This presents a treatment advantage over the drug alone but still has lingering issues and unknowns, including the destruction of healthy cells and tissue and the factors of pharmacokinetics, biodistribution, immunological and toxicological effects of DNA origami nanostructures remain unknown. Therefore, we are currently evaluating the effect of DNA nanostructures as a drug vehicle in vivo and, using targeting cell specific antibodies, further advanced our treatment efficacy in vitro leading to target specific drug delivery.